

13th Scientific Meeting

26 – 27 September 2013
Waldthausen/Mainz



CF Microbiome
CF related Basis Science
Clinical CF Research
and results of research projects
funded by the Mukoviszidose e.V.

Programme

Thursday, 26 September 2013

Opening

12:30 – 12:40 pm Horst Mehl, Chairman Mukoviszidose e.V.
Helge Hebestreit, member of the scientific
board of the Mukoviszidose e. V. (FGM)

CF related Basic Science

Moderation: Dominik Hartl (Tübingen)
Frank Wissing (Bonn)

- 12:40 – 1:00 pm** **Low surface pH, defective mucus layer, altered microbiome composition and distal colonic inflammation in mice deficient for the apical Cl-/HCO₃- exchanger Slc26a3**
Ursula Seidler (Hannover)
- 1:00 – 1:20 pm** **Targeting the Hsp90-Aha1 chaperone interaction by chemical biology to correct the misfolding CFTR Δ F508 protein in Cystic Fibrosis**
Wolfgang Obermann (Bochum)
- 1:20 – 1:40 pm** **Characterization of mechanosensitivity of CFTR**
Constanze Vitzthum (Gießen)
- 1:40 – 2:00 pm** **Screening and evaluation of Paullone derivatives as F508 Δ -CFTR correctors in CF**
Frederic Becq (Poitiers)
- 2:00 – 2:30 pm** **Coffee Break**
- 2:30 – 2:50 pm** **Towards the stabilization of CFTR with nanobodies**
Magdalena Grodecka (Brussels)
- 2:50 – 3:10 pm** **New opportunities for CFTR-targeting drug development using intestinal organoids**
Jeffrey M Beekman (Utrecht)
- 3:10 – 3:30 pm** **Citrate activates chloride and hyaluronan export of CFTR and corrects the Δ F508-CFTR defect**
Peter Prehm (Münster)

- 3:30 – 3:50 pm** **Cystic Fibrosis fibroblasts display altered proinflammatory and fibrogenic responses that are prevented by vardenafil**
Teresinha Leal (Brussels)
- 3:50 – 4:20 pm** **Coffee Break**
- 4:20 – 4:40 pm** **Vitamin D for the treatment of CF lung disease**
Julia Niederstraßer (Homburg)
- 4:40 – 5:00 pm** **Designer nucleases in CF research: Towards disease modeling and therapy.**
Toni Cathomen (Freiburg)

Clinical CF Research

- Moderation: Andreas Jung (Zürich)
Olaf Sommerburg (Heidelberg)
- 5:00 – 5:20 pm** **Lung diffusion capacity for CO/NO in cystic fibrosis patients**
Rainald Fischer (Munich)
- 5:20 – 5:40 pm** **Morphological and functional Magnetic Resonance Imaging of lung disease in infants and young children with Cystic Fibrosis (CF)**
Monika Eichinger (Heidelberg)
- 5:40 – 6:00 pm** **Newborn screening for cystic fibrosis in Switzerland – Evaluation of the two years pilot study**
Jürg Barben (St. Gallen)
- 6:00– 6:30 pm** **Coffee Break**

Keynote Session

- Moderation: Michael Hogardt (Frankfurt)
Barbara Kahl (Münster)
- 6:30 – 7:30 pm** **The Cystic Fibrosis Airway Microbiome: Clinical Opportunities and Challenges**
Michael G. Surette (Canada)
- 8:00 pm** **Dinner**

Friday, 27 September 2013

Clinical CF Research

- Moderation: Andreas Jung (Zürich)
Olaf Sommerburg (Heidelberg)
- 8:00 – 8:20 am** **Carbohydrate intake and required insulin dosage in cystic fibrosis-related diabetes compared to type 1 diabetes**
Nicole Scheuing (Ulm)
- 8:20 – 8:40 am** **Oral versus Insulin therapy of cystic fibrosis-related diabetes: A prospective, randomized and controlled long-term study**
Manfred Ballmann (Bochum)

CF Microbiology

- Moderation: Michael Hogardt (Frankfurt)
Barbara Kahl (Münster)
- 8:40 – 9:00 am** **Localisation of fungal pathogens in clinical samples by Fluorescence in situ hybridization**
Volker Rickerts (Berlin)
- 9:00 – 9:20 am** **Microevolution and Adaptation of Pseudomonas aeruginosa in CF-patients**
Sebastian Fischer (Hannover)
- 9:20 – 9:40 am** **Culture independent analysis of microbiota in CF patients**
Lutz von Müller (Homburg)
- 9:40 – 10:10 am** **Coffee Break**
- 10:10 – 10:30 am** **Dysbiosis in the faecal microbiota of cystic fibrosis patients**
Peter Vandamme (Ghent)
- 10:30 – 10:50 am** **ECFS Microbiome Diagnostic Working Group**
Kenneth Bruce (London)
- 10:50 – 11:10 am** **The growing threat of Nontuberculous mycobacteria in Cystic Fibrosis**
Andres Floto (Cambridge)
- 11:10 – 11:30 am** **Analysis of early and late Staphylococcus aureus isolates from cystic fibrosis patients**
Barbara Kahl (Münster)

11:30 – 11:50 am	Designing a MRSA eradication protocol in cystic fibrosis: The METRIC study Damian Downey (Belfast)
11:50 – 12:10 pm	Knowledge of the diversity of <i>P. aeruginosa</i> and its bacteriophages as a prerequisite towards the design of therapeutic cocktails Christine Pourcel (Paris)
12:10 – 12:30 pm	Prevention of <i>Staphylococcus aureus</i> infection using protective humanized antibodies and their respective epitopes for vaccination Alexander Klimka (Cologne)
12:30 pm	Closing of the meeting

This symposium is supported by



4.500 €



3.000 €



3.000 €



3.000 €



3.000 €